Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Regeneron Pharmaceuticals : shares poised for rebound - Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:04pm CEST

Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
05/25 REGENERON PHARMACEUTICALS : Report Summarizes Immunoglobulins Study Findings fro..
05/25 REGENERON PHARMACEUTICALS : Genetic Mutation Studies Help Validate New Strategy ..
05/25 SANOFI : FDA approves Sanofi and Regenerons Kevzara for adult rheumatoid arthrit..
05/24 REGENERON PHARMACEUTICALS : Announces ANGPTL3/Evinacumab Publication in New Engl..
05/24 SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 BIOTECH MOVERS : Puma Biotechnology Inc (NASDAQ:PBYI) and Regeneron Pharmaceutic..
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/22 REGENERON PHARMACEUTICALS : and Sanofi Announce FDA Approval of Kevzara® (sarilu..
05/19 REGENERON PHARMACEUTICALS : Pharma exec says industry must get fair about pricin..
05/18 REGENERON PHARMACEUTICALS : and Inovio Enter Immuno-Oncology Clinical Study Agre..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/24 After Hours Gainers / Losers
05/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
05/24 BBP : A Diversified Biotech ETF
05/23 Sanofi and Regeneron's RA med Kevzara faces crowded market
Advertisement
Financials ($)
Sales 2017 5 482 M
EBIT 2017 2 210 M
Net income 2017 1 019 M
Finance 2017 2 119 M
Yield 2017 -
P/E ratio 2017 51,81
P/E ratio 2018 40,36
EV / Sales 2017 8,45x
EV / Sales 2018 7,41x
Capitalization 48 437 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 441 $
Spread / Average Target -3,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..24.83%48 437
AMGEN, INC.6.31%114 303
CELGENE CORPORATION0.86%91 153
GILEAD SCIENCES, INC.-9.85%84 362
ACTELION LTD26.30%31 070
VERTEX PHARMACEUTICALS..59.90%29 540
More Results